Lilly Invests $1 billion to build a new manufacturing plant in North Carolina

0 49

Eli Lilly & Company plans to invest over $1 billion in Concord, North Carolina, to build a new manufacturing facility and almost 600 new employment. The company’s manufacturing capacity will be increased by utilizing cutting-edge technology to create parenteral (injectable) products and devices.

“Lilly is entering an exciting period of growth and we are committed to delivering innovative medicines to patients around the world. Expanding our manufacturing footprint in North Carolina enables us to continue to produce today’s medicines while providing additional capacity to manufacture the medicines of tomorrow. We are pleased to again partner with North Carolina to bring jobs to American workers and provide more medicines that patients need to address health challenges,”

said Edgardo Hernandez, senior vice president and president, Lilly Manufacturing Operations. 

Concord was chosen by Lilly because of the local labor force’s industrial technological experience, its proximity to institutions with excellent STEM programs, and its accessibility to significant transportation infrastructure. Lilly announced a $470 million investment in Research Triangle Park, North Carolina, in 2020. In addition to this location, the company will be able to build contacts with local governments and colleges, as well as diversify its growing footprint in the state, by opening a new facility in Concord.

Lilly plans to develop roughly 600 new employment for highly qualified individuals, including scientists, engineers, and manufacturing personnel, who will use modern technology to develop life-changing therapies and products that will improve people’s lives all around the world. In addition, 500 additional employment are expected to be needed while the facility is being built.

“Lilly’s choice brings more good jobs to North Carolina from one of our most important industries. North Carolina has become a premier hub for the world, thanks to our exceptional workforce and commitment to education,”

said North Carolina Governor Roy Cooper.

Lilly has invested more than $4 billion in worldwide production in the last five years, including more than $2 billion in the United States. In addition, the business announced today that it will invest $500 million in a new biopharmaceutical production plant in Limerick, Ireland. Lilly expects to invest more in manufacturing in the future to meet the need for potential new medications to treat diabetes, Alzheimer’s disease, cancer, and autoimmune diseases.

The investment in Concord is conditional on the execution of permitting and related approvals by the county and municipal governments. The Office of the Governor, the Department of Commerce, the Cabarrus Economic Development Corporation, the City of Concord, Cabarrus County, the Economic Development Partnership of North Carolina, the North Carolina Biotechnology Center, Rowan Cabarrus Community College, and the North Carolina Community College System collaborated with Lilly on the project.

Leave A Reply

Your email address will not be published.